Concepedia

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae‐Lyun Lee, Niven Mehra, Ray McDermott, Núria Sala‐González, Peter C.C. Fong, Richard Greil,

Journal of Clinical Oncology · 2023 · 121 citations · 24 references

DOIFull text

Open access

Abstract

Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.

References

24

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.3K citations · Full text

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Shiping Jiao, Weiya Xia, Hirohito Yamaguchi et al. · Clinical Cancer Research · 2017 · 943 citations · Full text

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Chris Parker, Elena Castro, Karim Fizazi et al. · Annals of Oncology · 2020 · 903 citations · Full text

, , +4

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 679 citations · Full text